Insurance premium financing of $506,190, due in monthly installments of $58,314, which includes principal and annual interest at 8.75% through April 2026
These liabilities consist primarily of account payables to research and development vendors, payroll and benefits accruals, professional service fees, and other general corporate obligations
Oragenics, Inc. has signed a Letter of Intent with Sigyn Therapeutics, Inc. to license CardioDialysis™, an extracorporeal blood purification technology
we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opportunities that may be new and separate from…
Reciprocal relationship from SIGY graph: Reciprocal relationship from OGEN graph: we seek to enhance shareholder value by evaluating business development opportunities both within and complementary t…
Oragenics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
OGEN-DEBT-11493
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2015-12-31.
OGEN-DEBT
Debt stack $227,348
90%
Market cache reports total debt of $227,348.
OGEN-DEBT-11492
Warrants outstanding: 13800000
90%
xbrl warrant detail from xbrl 2021-12-31.
Oragenics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Oragenics, Inc..
Oragenics, Inc. Ownership
Holder
Name
Confidence
Evidence
OGEN-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC
Geode Capital Management, LLC
90%
13F overlay lists Geode Capital Management, LLC as top holder; 10 tracked holders.
